Your browser doesn't support javascript.
loading
Validation of the Antineutrophil Cytoplasmic Antibody Renal Risk Score and Modification of the Score in a Chinese Cohort With a Majority of Myeloperoxidase-Positive Patients.
Ni, Anqi; Chen, Liangliang; Lan, Lan; Wang, Yaomin; Ren, Pingping; Zhu, Yilin; Xu, Ying; Shen, Xiaoqi; Zhou, Qin; Huang, Xiaohan; Wang, Huiping; Chen, Jianghua; Han, Fei.
Afiliação
  • Ni A; A. Ni, MD, L. Chen, MD, L. Lan, MD, Y. Wang, MD, P. Ren, MD, Y. Zhu, MD, Y. Xu, MD, X. Shen, MD, Q. Zhou, MD, X. Huang, MD, H. Wang, MD, J. Chen, MD, F. Han, MD, Kidney Disease Center, The First Affiliated Hospital, Zhejiang University School of Medicine, and Institute of Nephrology, Zhejiang Univer
  • Chen L; A. Ni, MD, L. Chen, MD, L. Lan, MD, Y. Wang, MD, P. Ren, MD, Y. Zhu, MD, Y. Xu, MD, X. Shen, MD, Q. Zhou, MD, X. Huang, MD, H. Wang, MD, J. Chen, MD, F. Han, MD, Kidney Disease Center, The First Affiliated Hospital, Zhejiang University School of Medicine, and Institute of Nephrology, Zhejiang Univer
  • Lan L; A. Ni, MD, L. Chen, MD, L. Lan, MD, Y. Wang, MD, P. Ren, MD, Y. Zhu, MD, Y. Xu, MD, X. Shen, MD, Q. Zhou, MD, X. Huang, MD, H. Wang, MD, J. Chen, MD, F. Han, MD, Kidney Disease Center, The First Affiliated Hospital, Zhejiang University School of Medicine, and Institute of Nephrology, Zhejiang Univer
  • Wang Y; A. Ni, MD, L. Chen, MD, L. Lan, MD, Y. Wang, MD, P. Ren, MD, Y. Zhu, MD, Y. Xu, MD, X. Shen, MD, Q. Zhou, MD, X. Huang, MD, H. Wang, MD, J. Chen, MD, F. Han, MD, Kidney Disease Center, The First Affiliated Hospital, Zhejiang University School of Medicine, and Institute of Nephrology, Zhejiang Univer
  • Ren P; A. Ni, MD, L. Chen, MD, L. Lan, MD, Y. Wang, MD, P. Ren, MD, Y. Zhu, MD, Y. Xu, MD, X. Shen, MD, Q. Zhou, MD, X. Huang, MD, H. Wang, MD, J. Chen, MD, F. Han, MD, Kidney Disease Center, The First Affiliated Hospital, Zhejiang University School of Medicine, and Institute of Nephrology, Zhejiang Univer
  • Zhu Y; A. Ni, MD, L. Chen, MD, L. Lan, MD, Y. Wang, MD, P. Ren, MD, Y. Zhu, MD, Y. Xu, MD, X. Shen, MD, Q. Zhou, MD, X. Huang, MD, H. Wang, MD, J. Chen, MD, F. Han, MD, Kidney Disease Center, The First Affiliated Hospital, Zhejiang University School of Medicine, and Institute of Nephrology, Zhejiang Univer
  • Xu Y; A. Ni, MD, L. Chen, MD, L. Lan, MD, Y. Wang, MD, P. Ren, MD, Y. Zhu, MD, Y. Xu, MD, X. Shen, MD, Q. Zhou, MD, X. Huang, MD, H. Wang, MD, J. Chen, MD, F. Han, MD, Kidney Disease Center, The First Affiliated Hospital, Zhejiang University School of Medicine, and Institute of Nephrology, Zhejiang Univer
  • Shen X; A. Ni, MD, L. Chen, MD, L. Lan, MD, Y. Wang, MD, P. Ren, MD, Y. Zhu, MD, Y. Xu, MD, X. Shen, MD, Q. Zhou, MD, X. Huang, MD, H. Wang, MD, J. Chen, MD, F. Han, MD, Kidney Disease Center, The First Affiliated Hospital, Zhejiang University School of Medicine, and Institute of Nephrology, Zhejiang Univer
  • Zhou Q; A. Ni, MD, L. Chen, MD, L. Lan, MD, Y. Wang, MD, P. Ren, MD, Y. Zhu, MD, Y. Xu, MD, X. Shen, MD, Q. Zhou, MD, X. Huang, MD, H. Wang, MD, J. Chen, MD, F. Han, MD, Kidney Disease Center, The First Affiliated Hospital, Zhejiang University School of Medicine, and Institute of Nephrology, Zhejiang Univer
  • Huang X; A. Ni, MD, L. Chen, MD, L. Lan, MD, Y. Wang, MD, P. Ren, MD, Y. Zhu, MD, Y. Xu, MD, X. Shen, MD, Q. Zhou, MD, X. Huang, MD, H. Wang, MD, J. Chen, MD, F. Han, MD, Kidney Disease Center, The First Affiliated Hospital, Zhejiang University School of Medicine, and Institute of Nephrology, Zhejiang Univer
  • Wang H; A. Ni, MD, L. Chen, MD, L. Lan, MD, Y. Wang, MD, P. Ren, MD, Y. Zhu, MD, Y. Xu, MD, X. Shen, MD, Q. Zhou, MD, X. Huang, MD, H. Wang, MD, J. Chen, MD, F. Han, MD, Kidney Disease Center, The First Affiliated Hospital, Zhejiang University School of Medicine, and Institute of Nephrology, Zhejiang Univer
  • Chen J; A. Ni, MD, L. Chen, MD, L. Lan, MD, Y. Wang, MD, P. Ren, MD, Y. Zhu, MD, Y. Xu, MD, X. Shen, MD, Q. Zhou, MD, X. Huang, MD, H. Wang, MD, J. Chen, MD, F. Han, MD, Kidney Disease Center, The First Affiliated Hospital, Zhejiang University School of Medicine, and Institute of Nephrology, Zhejiang Univer
  • Han F; A. Ni, MD, L. Chen, MD, L. Lan, MD, Y. Wang, MD, P. Ren, MD, Y. Zhu, MD, Y. Xu, MD, X. Shen, MD, Q. Zhou, MD, X. Huang, MD, H. Wang, MD, J. Chen, MD, F. Han, MD, Kidney Disease Center, The First Affiliated Hospital, Zhejiang University School of Medicine, and Institute of Nephrology, Zhejiang Univer
J Rheumatol ; 50(5): 662-670, 2023 05.
Article em En | MEDLINE | ID: mdl-36642437
ABSTRACT

OBJECTIVE:

We aimed to validate and modify the renal risk score for antineutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis (AAGN) in a Chinese cohort with a majority of myeloperoxidase (MPO)-positive patients.

METHODS:

A total of 285 patients with biopsy-proven AAGN in our center were retrospectively included. Patients were randomly assigned to the development set (n = 201) and the validation set (n = 84). We calculated the renal risk score and analyzed the clinicopathological characteristics and follow-up data. The nomogram was constructed based on the independent prognostic factors identified by the multivariable Cox regression and then compared with the renal risk score.

RESULTS:

Over a median follow-up period of 41.3 (range 20.0-63.8) months, 84 (29.5%) patients reached end-stage kidney disease (ESKD). In the development set, hypertension (hazard ratio [HR] 2.16, 95% CI 1.08-4.32, P = 0.03), high serum creatinine (HR 1.002, 95% CI 1.001-1.003, P < 0.001), high daily urine protein (HR 1.34, 95% CI 1.15-1.57, P < 0.001), high glomerular sclerosis (HR 13.98, 95% CI 3.50-55.92, P < 0.001), and interstitial fibrosis > 50% (HR 4.18, 95% CI 1.90-9.19, P < 0.001) were independent risk factors for ESKD, and these indicators were included in the nomogram. The C-indices of the nomogram model in the development set, validation set, and all-data set were 0.838 (range 0.785-0.891), 0.794 (range 0.774-0.814), and 0.822 (range 0.775-0.869), respectively, which were higher than those of the renal risk score model, 0.801 (range 0.748-0.854), 0.746 (range 0.654-0.838) and 0.783 (range 0.736-0.830), respectively. The net reclassification improvement and the integrated discrimination improvement further illustrated the higher predictive ability of the nomogram.

CONCLUSION:

We present a nomogram as a practical tool to predict renal outcomes in Chinese patients with MPO-ANCA glomerulonephritis.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vasculite Associada a Anticorpo Anticitoplasma de Neutrófilos / Glomerulonefrite / Falência Renal Crônica Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: J Rheumatol Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vasculite Associada a Anticorpo Anticitoplasma de Neutrófilos / Glomerulonefrite / Falência Renal Crônica Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: J Rheumatol Ano de publicação: 2023 Tipo de documento: Article